Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

Validation of cytogenetic-based risk stratification in primary myelofibrosis

(2010) E. Rumi et al.   BLOOD

Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act

(2010) A Tefferi   BONE MARROW TRANSPLANTATION

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

(2010) A Tefferi et al.   LEUKEMIA

Outcome of Transplantation for Myelofibrosis

(2009) Karen K. Ballen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis

(2009) K. Hussein et al.   BLOOD

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

(2009) P. Guglielmelli et al.   BLOOD

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

(2009) C. S. Tam et al.   BLOOD

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan

(2009) Tomonori Hidaka et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

(2009) Constantine S. Tam et al.   JOURNAL OF CLINICAL ONCOLOGY

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival

(2009) A Tefferi et al.   LEUKEMIA

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

(2009) A Tefferi et al.   LEUKEMIA

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD

Risk factors for leukemic transformation in patients with primary myelofibrosis

(2008) Jocelin Huang et al.   CANCER

Choosing between stem cell therapy and drugs in myelofibrosis

(2008) N Kröger et al.   LEUKEMIA

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

(2008) T L Lasho et al.   LEUKEMIA

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

(2008) F Cervantes et al.   LEUKEMIA

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

(2008) A M Vannucchi et al.   LEUKEMIA